Literature DB >> 21721934

Ethnic disparities in breast tumor phenotypic subtypes in Hispanic and non-Hispanic white women.

Lisa M Hines1, Betsy Risendal, Tim Byers, Sarah Mengshol, Jan Lowery, Meenakshi Singh.   

Abstract

AIMS: Hispanic women are at a lower risk of getting breast cancer than non-Hispanic white (NHW) women, yet they experience a higher risk of mortality after diagnosis. There is some evidence to suggest differences in tumor pathology; however, very limited research has been published on Hispanic women. This represents one of the first studies to evaluate the prevalence of tumor markers and phenotypic subtypes that are associated with poorer prognosis (human epidermal growth factor receptor 2 [HER2], triple negative and basal-like tumors) among Hispanic women.
METHODS: We reviewed pathology reports, obtained paraffin blocks of breast cancer tissue, and established tissue microarrays from NHW (n=119) and Hispanic women (n=69) who were Colorado participants in the 4-Corners Breast Cancer Study. We evaluated ethnic differences in the prevalence of tumor markers and phenotypic subtypes and assessed the contribution of risk factors in explaining the observed differences.
RESULTS: Consistent with other studies, Hispanic women had a higher prevalence of estrogen receptor-negative tumors compared with NHWs (36.2% vs. 22.7%, p=0.05). Hispanics also had an unexpectedly higher proportion of HER2-positive tumors compared with NHWs (31.9% vs. 14.3%, p<0.01). Independent of other prognostic factors, Hispanics were 2.8 times more likely to have a HER2-positive tumor (95% confidence interval [CI] 0.98-7.86). Hispanics were less likely to have the more favorable luminal A subtype, but no significant differences were observed for the less favorable basal-like or triple negative subtypes. However, there were suggestive differences when considering menopausal status.
CONCLUSIONS: These findings provide evidence that breast cancers among Hispanic women comprise a distinct spectrum of tumor subtypes when compared with NHW women.

Entities:  

Mesh:

Year:  2011        PMID: 21721934      PMCID: PMC3186448          DOI: 10.1089/jwh.2010.2558

Source DB:  PubMed          Journal:  J Womens Health (Larchmt)        ISSN: 1540-9996            Impact factor:   2.681


  38 in total

1.  Survival differences in breast cancer among racial/ethnic groups: a population-based study.

Authors:  A Boyer-Chammard; T H Taylor; H Anton-Culver
Journal:  Cancer Detect Prev       Date:  1999

2.  Tissue microarrays for rapid linking of molecular changes to clinical endpoints.

Authors:  J Torhorst; C Bucher; J Kononen; P Haas; M Zuber; O R Köchli; F Mross; H Dieterich; H Moch; M Mihatsch; O P Kallioniemi; G Sauter
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

Review 3.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).

Authors:  M Elizabeth H Hammond; Daniel F Hayes; Mitch Dowsett; D Craig Allred; Karen L Hagerty; Sunil Badve; Patrick L Fitzgibbons; Glenn Francis; Neil S Goldstein; Malcolm Hayes; David G Hicks; Susan Lester; Richard Love; Pamela B Mangu; Lisa McShane; Keith Miller; C Kent Osborne; Soonmyung Paik; Jane Perlmutter; Anthony Rhodes; Hironobu Sasano; Jared N Schwartz; Fred C G Sweep; Sheila Taube; Emina Emilia Torlakovic; Paul Valenstein; Giuseppe Viale; Daniel Visscher; Thomas Wheeler; R Bruce Williams; James L Wittliff; Antonio C Wolff
Journal:  Arch Pathol Lab Med       Date:  2010-07       Impact factor: 5.534

4.  Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study.

Authors:  Limin X Clegg; Frederick P Li; Benjamin F Hankey; Kenneth Chu; Brenda K Edwards
Journal:  Arch Intern Med       Date:  2002-09-23

5.  Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups.

Authors:  K C Chu; W F Anderson; A Fritz; L A Ries; O W Brawley
Journal:  Cancer       Date:  2001-07-01       Impact factor: 6.860

6.  Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial/ethnic groups.

Authors:  Kenneth C Chu; William F Anderson
Journal:  Breast Cancer Res Treat       Date:  2002-06       Impact factor: 4.872

7.  Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older.

Authors:  Christopher I Li; Kathleen E Malone; Janet R Daling
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-07       Impact factor: 4.254

8.  Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35.

Authors:  Vickie L Shavers; Linda C Harlan; Jennifer L Stevens
Journal:  Cancer       Date:  2003-01-01       Impact factor: 6.860

9.  Variation in breast cancer subtypes with age and race/ethnicity.

Authors:  Carol A Parise; Katrina R Bauer; Vincent Caggiano
Journal:  Crit Rev Oncol Hematol       Date:  2009-10-02       Impact factor: 6.312

10.  Differences in breast cancer stage, treatment, and survival by race and ethnicity.

Authors:  Christopher I Li; Kathleen E Malone; Janet R Daling
Journal:  Arch Intern Med       Date:  2003-01-13
View more
  22 in total

1.  Genomic Disparities in Breast Cancer Among Latinas.

Authors:  Filipa Lynce; Kristi D Graves; Lina Jandorf; Charite Ricker; Eida Castro; Laura Moreno; Bianca Augusto; Laura Fejerman; Susan T Vadaparampil
Journal:  Cancer Control       Date:  2016-10       Impact factor: 3.302

2.  Construction and Validation of a Multi-Institutional Tissue Microarray of Invasive Ductal Carcinoma From Racially and Ethnically Diverse Populations.

Authors:  Edward Seijo; Diana Lima; Egiebade Iriabho; Jonas Almeida; Jesus Monico; Margarita Echeverri; Sylvia Gutierrez; Idhaliz Flores; Ji-Hyun Lee; Kate Fisher; William E Grizzle; Gabriel L Sica; Charles Butler; Chindo Hicks; Cathy D Meade; Stephen Olufemi Sodeke; Krzysztof Moroz; Domenico Coppola; Teresita Munoz-Antonia
Journal:  Cancer Control       Date:  2016-10       Impact factor: 3.302

3.  Pretreatment levels of circulating Th1 and Th2 cytokines, and their ratios, are associated with ER-negative and triple negative breast cancers.

Authors:  Chi-Chen Hong; Song Yao; Susan E McCann; Ree Y Dolnick; Paul K Wallace; Zhihong Gong; Lei Quan; Kelvin P Lee; Sharon S Evans; Elizabeth A Repasky; Stephen B Edge; Christine B Ambrosone
Journal:  Breast Cancer Res Treat       Date:  2013-04-30       Impact factor: 4.872

4.  Levels of lymphocyte subsets in peripheral blood prior treatment are associated with aggressive breast cancer phenotypes or subtypes.

Authors:  Yijun Jia; Lei Xu; Qing Lin; Mingjie Zhu; Longlong Ding; Kejin Wu; Yunshu Lu
Journal:  Med Oncol       Date:  2014-05-06       Impact factor: 3.064

5.  Healthy lifestyle impact on breast cancer-specific and all-cause mortality.

Authors:  Adaline E Heitz; Richard N Baumgartner; Kathy B Baumgartner; Stephanie D Boone
Journal:  Breast Cancer Res Treat       Date:  2017-08-31       Impact factor: 4.872

6.  Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Is Associated with Indigenous American Ancestry in Latin American Women.

Authors:  Katie M Marker; Valentina A Zavala; Tatiana Vidaurre; Paul C Lott; Jeannie Navarro Vásquez; Sandro Casavilca-Zambrano; Mónica Calderón; Julio E Abugattas; Henry L Gómez; Hugo A Fuentes; Ruddy Liendo Picoaga; Jose M Cotrina; Silvia P Neciosup; Carlos A Castañeda; Zaida Morante; Fernando Valencia; Javier Torres; Magdalena Echeverry; Mabel E Bohórquez; Guadalupe Polanco-Echeverry; Ana P Estrada-Florez; Silvia J Serrano-Gómez; Jenny A Carmona-Valencia; Isabel Alvarado-Cabrero; María Carolina Sanabria-Salas; Alejandro Velez; Jorge Donado; Sikai Song; Daniel Cherry; Lizeth I Tamayo; Scott Huntsman; Donglei Hu; Roberto Ruiz-Cordero; Ronald Balassanian; Elad Ziv; Jovanny Zabaleta; Luis Carvajal-Carmona; Laura Fejerman
Journal:  Cancer Res       Date:  2020-04-03       Impact factor: 12.701

7.  High prevalence of luminal B breast cancer intrinsic subtype in Colombian women.

Authors:  Silvia Juliana Serrano-Gomez; Maria Carolina Sanabria-Salas; Gustavo Hernández-Suarez; Oscar García; Camilo Silva; Alejandro Romero; Juan Carlos Mejía; Lucio Miele; Laura Fejerman; Jovanny Zabaleta
Journal:  Carcinogenesis       Date:  2016-04-16       Impact factor: 4.944

8.  Associations between CYP19A1 polymorphisms, Native American ancestry, and breast cancer risk and mortality: the Breast Cancer Health Disparities Study.

Authors:  Stephanie D Boone; Kathy B Baumgartner; Richard N Baumgartner; Avonne E Connor; Christina M Pinkston; Shesh N Rai; Elizabeth C Riley; Lisa M Hines; Anna R Giuliano; Esther M John; Mariana C Stern; Gabriela Torres-Mejía; Roger K Wolff; Martha L Slattery
Journal:  Cancer Causes Control       Date:  2014-08-05       Impact factor: 2.506

9.  Differences between Hispanic and non-Hispanic white women with breast cancer for clinical characteristics and their correlates.

Authors:  Avonne E Connor; Richard N Baumgartner; Dongyan Yang; Martha L Slattery; Anna R Giuliano; Betsy C Risendal; Madiha M Abdel-Maksoud; Kathy B Baumgartner
Journal:  Ann Epidemiol       Date:  2013-01-28       Impact factor: 3.797

Review 10.  Breast Cancer in Latinas: A Focus on Intrinsic Subtypes Distribution.

Authors:  Silvia J Serrano-Gómez; Laura Fejerman; Jovanny Zabaleta
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-10-20       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.